

Portrait of a Canine Probiotic – from Gut to Gut

D. O'Mahony, K. Barry Murphy, J. Macsharry, T. Boileau, G. Sunvold, G. Reinhart, B. Kiely, F. Shanahan, L. O'Mahony

▶ To cite this version:

D. O'Mahony, K. Barry Murphy, J. Macsharry, T. Boileau, G. Sunvold, et al.. Portrait of a Canine Probiotic – from Gut to Gut. Veterinary Microbiology, 2009, 139 (1-2), pp.106. 10.1016/j.vetmic.2009.05.002 . hal-00520659

HAL Id: hal-00520659 https://hal.science/hal-00520659

Submitted on 24 Sep 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Portrait of a Canine Probiotic *Bifidobactium* – from Gut to Gut

Authors: D. O'Mahony, K. Barry Murphy, J. MacSharry, T. Boileau, G. Sunvold, G. Reinhart, B. Kiely, F. Shanahan, L. O'Mahony

PII:	\$0378-1135(09)00253-3
DOI:	doi:10.1016/j.vetmic.2009.05.002
Reference:	VETMIC 4437
To appear in:	VETMIC
Received date:	6-2-2009
Revised date:	28-4-2009
Accepted date:	11-5-2009



Please cite this article as: O'Mahony, D., Murphy, K.B., MacSharry, J., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., Portrait of a Canine Probiotic *Bifidobactium* – from Gut to Gut, *Veterinary Microbiology* (2008), doi:10.1016/j.vetmic.2009.05.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1	Portrait of a Canine Probiotic <i>Bifidobactium</i> – from Gut to Gut
2	
3	D. O'Mahony ¹ , K. Barry Murphy ¹ , J. MacSharry ¹ , T. Boileau ² , G. Sunvold ² , G. Reinhart ² , B.
4	Kiely ¹ , F. Shanahan ³ , L. O'Mahony ^{1, 3} .
5	
6	¹ Alimentary Health Ltd., National University of Ireland, Cork, Ireland
7	² Procter & Gamble Pet Care, Lewisburg, Ohio, USA.
8	³ Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland
9 10	Keywords: Probiotics, Canine, Bifidobacteria, Lactobacillus
11	
12	Current Address of Corresponding Author:
13	Dr. Liam O'Mahony
14	Swiss Institute of Allergy and Asthma Research (SIAF),
15	Davos CH-7270, Switzerland.
16	Telephone: 0041 814100853
17	Fax: 0041 814100840
18	E-mail: liam.omahony@siaf.uzh.ch

19 Abstract

The gastrointestinal environment is a complex interactive system involving the host, ingested 20 dietary components, and numerous microbial species. We hypothesised that isolation and 21 screening of Lactobacilli and Bifidobacteria adherent to healthy canine gastrointestinal tissue 22 would yield strains with commensal activity in canines. The aims of this study were 1) to 23 isolate a bank of commensal organisms from the canine gastrointestinal tract; 2) to 24 25 screen these novel microbial isolates for potential probiotic effects; 3) to select one organism from these screens and test its impact on the canine microbiota. Lactic acid 26 bacteria (LAB) were isolated from resected canine gastrointestinal tissue and screened in 27 *vitro* for putative probiotic activities. Murine studies examined gastrointestinal transit and 28 inhibition of Salmonella typhimurium translocation. One strain was progressed to a canine 29 study where its impact on the gastrointestinal microbiota was determined. Of the 420 isolates 30 31 from the canine gut, 62 strains were characterised as LAB. Following assessment of the strain bank with regard to pH sensitivity, bile resistance, pathogen inhibition and 32 survival following freeze drying, 4 Lactobacillus strains and 2 Bifidobacteria strains 33 were selected for further examination. Bifidobacterium animalis AHC7 adhered to 34 epithelial cells, transited the murine gastrointestinal tract to high numbers and significantly 35 reduced Salmonella typhimurium translocation. Bifidobacterium animalis AHC7 36 consumption significantly reduced the carriage of *Clostridia*, in particular *C. difficile*, in 37 dogs. This study describes the isolation and screening of canine-derived bacterial strains with 38 commensal traits. The results demonstrate that Bifidobacterium animalis AHC7 has 39 significant potential for improving canine gastrointestinal health. 40

41 1. Introduction

The gastrointestinal tract harbours a diverse bacterial community that, in humans, comprises 42 more than 1000 different species, and outnumbers human somatic and germ cells tenfold 43 44 (O'Hara and Shanahan, 2006). Under normal circumstances, commensal bacteria are an essential health asset that exert a conditioning and protective influence on intestinal structure 45 and homeostasis. Intestinal bacteria protect against infection, and actively exchange 46 developmental and regulatory signals with the host that prime and instruct mucosal 47 immunity. 48 At the turn of the last century, the use of "friendly" microbes present in fermented foods for 49 the purpose of health maintenance and disease prevention was first proposed by Metchnikoff 50 (1907). These beliefs have been substantiated by recent research, which indicates that 51 enhancing the beneficial components of the gut microbiota using probiotics represents a 52 realistic therapeutic strategy in the maintenance of human health and in the treatment of 53 various intestinal disorders (Dunne et al., 2001; O'Mahony et al., 2005; Whorwell et al., 54 2006; O'Hara and Shanahan, 2007). However, the use of probiotics in companion animals 55 has received less attention. Indeed, it is apparent that certain strains may exert some effect on 56 the canine microbiota (Baillon et al., 2004) while many existing probiotic strains have little or 57 no beneficial effect on the composition of the canine microbiota (Swanson et al., 2002; 58 Vahjen and Männer, 2003; Pascher et al., 2008). 59 Some investigators have hypothesized that commensal organisms may exert species-60 61 specific effects and therefore a successful canine probiotic organism would ideally be derived from the canine gastrointestinal tract (McCoy and Gilliland 2007). This is supported by a 62

recent review of published 16s rRNA gene sequences which demonstrates that the canine

64 microbiota is closely related to, but distinct from, the microbiota of other mammals such as

humans (Ley et al., 2008). However, while the resident microbiota may be different in

66 composition between different species, it has never been formally demonstrated that probiotic effects are species specific. Nevertheless, the generation of a bank of lactic 67 acid bacteria from the canine gastrointestinal tract would most likely yield microbes 68 69 that would compete successfully and thrive within this environment. Therefore, the purpose of the present study was to isolate a bank of commensal organisms from the 70 canine gastrointestinal tract and to screen these novel microbial isolates for potential 71 probiotic effects using in vitro assays and murine models. In order to further validate 72 our screening approach, we selected one commensal microbe and examined its impact 73 74 on the canine microbiota following oral consumption in a clinical study.

75

Page 4 of 28

76 2. Materials and Methods

77 2.1 Isolation and identification of bacteria from healthy dogs

Gastrointestinal sections were obtained from canine cadavers (n=7) obtained from local 78 veterinarians after euthanasia was performed for reasons unrelated to this study. No dog 79 exhibited evidence of gastrointestinal disease and all gastrointestinal tissues appeared normal. 80 The caecum, mid-colon and terminal colons were isolated, dissected and the tissue washed in 81 Ringers solution (Oxoid, Cambridge, UK) to remove loosely adherent bacteria. Following 82 the washing step, bacteria that were still present on the tissue were termed "adherent 83 bacteria" as these bacteria were not removed by gentle agitation. Tissue was 84 85 homogenised using mechanical means (i.e. a food grade blender) and supernatants containing adherent bacteria were plated on selective agars. Serial 10-fold dilutions 86 were performed in Ringers solution and each dilution was inoculated onto MRS agar 87 88 (Oxoid) with 0.05% (v/v) cysteine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) or Reinforced Clostridial Agar (RCA; Oxoid) with 0.05% cysteine. All plates were 89 90 incubated **anaerobically** at 37°C for 48 hours (h). Isolated colonies were re-streaked for 6 91 generations in order to isolate purified individual bacterial strains. Following this purification, single strain cultures were identified using morphology, gram reaction, catalase 92 activity, API 50CHL fermentation profiles (Biomerieux, St. Laurent, Quebec) and 93 phosphofructoketolase test positivity. 94

95

96 2.2 In vitro assessment of bacterial isolates

In order to determine the ability of the LAB isolates to survive transit through the upper
gastrointestinal tract we assessed strain tolerances to low pH and bile. Forthy eight hour
cultures of each strain grown in MRS broth with 0.05% (v/v) cysteine were resuspended in

100 MRS broth (Lactobacilli) or trypticase-phytone-yeast extract broth (Becton-Dickenson, Oxford, UK) for Bifidobacteria adjusted with 1N HCl to pH 2.5. Survival was measured 101 after 0, 30, 60, 120, 180, 240, and 360 minutes by plate count method. Resistance to bile was 102 103 examined using RCA plates supplemented with 0.5, 1 or 5% porcine bile (Sigma-Aldrich). Bacterial strains grown in MRS broth with 0.05% cysteine were centrifuged and pellets 104 were re-suspended in a cryoprotectant (18% reconstituted skim milk, 2% sucrose). Bacteria 105 were frozen at -20°C for 24 h and freeze dried for another 24 h. Sterile polypropylene tubes 106 were filled with each bacterial powder and wrapped in aluminium foil before being 107 108 placed in storage. Bacterial numbers were assessed immediately following fermentation, immediately following freeze drying and following one month storage at 21°C by plating 109 on MRS agar (Lactobacilli) or MRS agar with cysteine (Bifidobacteria). 110 The in vitro antagonistic activity against pathogenic indicator organisms was examined 111 by measuring the zone of inhibition surrounding the test strain colonies. The pathogens 112 E.coli 0157H45, Listeria monocytogenes, Listeria inocua and Salmonella typhimurium were 113 used as indicator organisms to test the antagonistic activities of each LAB isolate. Indicator 114 organisms were grown in TSA (E.coli 0157H45 and S. typhimurium) or BHI (L. 115 *monocytogenes* and L. *inocua*) in sloppy agar broths (0.7% w/v) and were overlaid on to the 116 LAB plates. Cell free supernatants from the LAB strains were also tested. The supernatants 117 were buffered with 2% β-glycerophosphate to inhibit the effect of acid production. 118

119

120 2.3 Sequence identification of selected probiotic strains

121 The intergenic spacer 16-23s rDNA region was sequenced for six strains selected on the

122 basis of their favourable results in the preceding assays. Bacterial suspensions were

- frozen at -70°C for 10 minutes, thawed and resuspended in Buffer PB from the Qiagen PCR
- 124 purification kit (Qiagen, Sussex, UK). The lysate was centrifuged, washed with Buffer PE
- and the DNA eluted using Buffer EB. PCR was performed using the intergenic spacer (IGS)
- 126 primers, IGS L: 5'-GCTGGATCACCTCCTTTC-3' and IGS R: 5'-
- 127 CTGGTGCCAAGGCATCCA-3' (bifidobacteria); 5'- AGA GTT TGA T(CT) (AC) TGG
- 128 CTC AG- 3' and 5'- CAC CGC TAC ACA TGG AG-3' (lactobacilli). The cycling
- 129 conditions were 96°C for 1 min (1 cycle), 94°C for 30 sec, 53°C for 30 sec, 72°C for 30 sec
- 130 (28 cycles) using a Hybaid thermocycler. The PCR products were cut out of the gel and the
- 131 DNA purified using the Qiagen Gel extraction kit. Purified products were sequenced by
- 132 LARK Technologies Inc. The resultant DNA sequence data was submitted to the NCBI
- standard nucleotide-to-nucleotide homology BLAST search engine
- 134 (<u>http://www.ncbi.nlm.nih.gov/BLAST/</u>). The nearest match to the sequence was identified
- and sequences were aligned using DNASTAR MegAlign software.
- 136
- 137 2.4 Adherence to intestinal epithelial cells

The human epithelial cell line, HT-29 (ATTC, Manassas, USA), were cultured in Dulbecco's 138 modified Eagle's minimal essential medium (DMEM, GIBCO-BRL, UK), containing 25 mM 139 glucose, 10% (v/v) heat-inactivated fetal calf serum (GIBCO-BRL) and 1% 140 penicillin/streptomycin (Sigma-Aldrich). Following the 7 day differentiation period, the 141 epithelial monolayers were washed with antibiotic-free DMEM. Cultures of the six test 142 bacterial strains were washed twice in PBS before being resuspended in antibiotic-free 143 DMEM at a concentration of 1×10^6 CFU/ml. Bacterial suspensions were added to the 144 epithelial cells for 90 minutes at 37°C and each experiment was performed in triplicate. The 145 well characterised adherent lactobacillus strain UCC118 (Van Pijkeren et al., 2006) was 146

included as a positive control. Following incubation the epithelial monolayers were washed
to remove the non-adherent cells. Epithelial cells were lysed using sterile dH₂O and the
number of bacterial cells remaining were quantified by plating on MRS agar (Lactobacilli) or
MRS agar containing cysteine (Bifidobacteria).

151

152 2.5 Gastrointestinal transit in mice

A rifampicin resistant variant of the six test probiotic cultures were generated to facilitate 153 uncomplicated identification of the strain in fecal cultures. These were generated by plating 154 the bacteria on RCA plates supplemented with 0.05% cysteine and increasing concentrations 155 of rifampicin (Sigma-Aldrich). Freeze-dried cultures of each Rif^R were provided in the 156 drinking water at a dose of 5×10^8 live bacterial cells per day for a period of 7 days. Faecal 157 samples were obtained from all animals (n=8 animals per group) prior to the start of probiotic 158 administration (day 0) and on days 1, 4 and 7 of administration and 5 days post-cessation of 159 feeding. Faecal samples were weighed, homogenised, diluted in ringers and spread plated on 160 RCA supplemented with 0.05% cysteine and 75µg/ml rifampicin. The plates were incubated 161 anaerobically at 37°C for 48 h. 162

163

164 2.6 Murine Salmonella typhimurium challenge

Female Balb/C mice 6-8 weeks of age (Harlan, Oxon, UK) were housed in 12 h light/dark
cycle and provided standard laboratory chow and water *ad libitum*. All murine experiments
were approved by the University College Cork animal ethics committee and
experimental procedures were conducted under appropriate license from the Irish
government. Groups of animals (n=12 per group) were administered one of the six test

170 probiotic cultures (in a freeze-dried format) or a placebo excipient control suspended in drinking water on a daily basis for a period of 4 weeks. After 3 weeks of probiotic pre-171 feeding all mice were orally challenged with 1×10^7 CFU Salmonella using a previously 172 described method (O'Mahony et al., 2008). After 7 days all mice were euthanised by cervical 173 dislocation and spleens and livers removed. Aliquots of tissue homogenates were serially 174 diluted in ringers solution and spread plated on McConkey agar (Oxoid). The plates were 175 incubated aerobically at 37°C for 24 h allowing the quantification of Salmonella load in the 176 tissues. 177

178

179 2.7 Influence of probiotic consumption on the canine microbiota

Eleven dogs (4 females, 7 males, average age 8.4 years) were fed a commercially available 180 Eukanuba Premium Performance diet for 6 weeks prior to enrolment in this study. In addition 181 to the base diet, each dog received 1.5×10^9 CFU of *Bifidobacterium animalis* AHC7 / day in a 182 pill format for 6 weeks. Daily food intake and weekly body weights were measured during 183 the entire experiment. Fresh faecal samples were collected before (day -10 and day -1) and 184 after probiotic feeding at weeks 4, 5, and 6. For bacterial enumeration, 10 g of feces was 185 homogenized in 90 ml of Butterfield's Phosphate-Buffered Dilution Water and serially 186 diluted. Spread plates were used to evaluate total anaerobes on CDC Anaerobic Blood Agar 187 (Anaerobe Systems AS646; San Jose, CA), Bifidobacterium spp. on Bifid Selective Agar 188 (Anaerobe Systems AS6423), *Lactobacillus spp.* on BBL[™] LBS Agar (Becton Dickinson) 189 211327; Sparks, MD with Glacial Acetic Acid (J.T. Baker NJ 9522-33; Phillipsburg, NJ), 190 Bacteroides fragilis group on Bacteroides Bile Esculin Agar (BBE) (BD 221836), 191 Clostridium spp. on Clostrisel Agar (BBL Microbiology Systems 21114; Cockeysville, MD), 192 Clostridium difficile on Clostridium Difficile Agar Base (Oxoid CM601; Oxoid Ltd., 193

194 Basingstoke, Hampshire, England) with Clostridium Difficile Supplement (Oxoid SR96) and

- defibrinated horse blood (Oxoid SR50), *Escherichia coli* on Hardy ECC Chromagar (Hardy
- Diagnostics G137; Santa Maria, CA) and total aerobes on Difco[™] Plate Count Agar (BD
- 197 24790). CDC Anaerobic Blood Agar, Bifid Selective Agar, LBS Agar, BBE Agar, Clostrisel
- 198 Agar, and Clostridium Difficile Agar were incubated anaerobically at 37°C for 48 h. ECC
- 199 Chromagar and PCA were incubated aerobically at 37°C for 24 h and 48 h, respectively.
- 200 Pour plates containing 1 ml of inoculum were used to evaluate *Clostridium perfringens* on
- 201 Perfringens Agar (OPSP) (Oxoid CM0543) with Perfringens Selective Supplement A (Oxoid
- SR0076E), and Perfringens Selective Supplement B (Oxoid SR0077E). OPSP plates were
- 203 incubated under anaerobic conditions at 37°C for 24 h. This study was approved by the

204 Procter & Gamble Pet Care Animal Care and Use Committee.

205

206 *2.10 Statistical analysis*

- 207 Statistical analysis of the *in vitro* results and the murine data was performed using unpaired
- student t-tests. Baseline microbial data in the canine study was analysed by ANOVA and
- 209 GLM procedures using SAS software (SAS Institute, Cary, NC, USA).
- 210

211 3. **Results**

212 *3.1 Bacterial Isolation from the Canine Gastrointestinal Tract*

A total of 420 isolated colonies from the canine gastrointestinal tract were purified and
examined for colony morphology, gram stain appearance and catalase activity. Of these, 62
strains displayed the correct colony morphology and were gram positive and catalase
negative. Preliminary species identification revealed that the bank of strains isolated from the
canine gut contained 30 *Leuconostoc lactis* strains, 9 *Lactobacillus acidophilus* strains, 7 *Lactococcus crispatus* strains, 5 *Bifidobacteria* strains, 4 *Lactobacillus fermentum* strains and
2 *Lactococcus buchneri* strains while the identity of 5 strains remained ambiguous.

220

221 3.2 In vitro assessment of bacterial isolates

The majority of the canine isolates exhibited strong tolerance to low pH conditions in 222 vitro. Of the 62 strains tested only 8 strains showed poor survival in an acidic 223 environment. In contrast to the results observed regarding resistance to low pH 224 conditions, many of the strains tested were sensitive to low concentrations of bile. 225 In order to identify strains that could survive technological process we determined the 226 227 ability of each strain to survive freeze-drying and storage for one month. The majority of the strains grew well in the overnight cultures but 4 strains demonstrated poor 228 growth prior to freeze-drying. The two strains which demonstrated superior recovery 229 following freeze drying were AHCB and AHC7. Storage at room temperature (21°C) 230 for one month was relatively well tolerated by most of the strains with only 4 strains 231 decreasing in number by more than 1 log value (AHC3312, AHC5212, AHC5223 and 232 AHCB). 233

The majority of the strains exhibited antagonistic activity, as determined by a clear zone of inhibition surrounding the test organism, against *Salmonella typhimurium, E. Coli* 0157:H45, *Listeria monocytogenes* and *Listeria inocua*. Seven strains exhibited minimal activity against these pathogens (AHC5121, AHC5223, AHC5333, AHC6322, AHC6341, AHCA and AHCC). Buffering of acid production by the test strains significantly decreased the zone of inhibition indicating that the mechanism of inhibition is primarily due to metabolite production.

241 From the data generated on the *in vitro* assessments described above, 6 strains were

selected for further study. These strains were AHC1222, AHC3133, AHC5323,

243 AHC6331, AHCF and AHC7.

244

245 3.3 Sequence identification of selected probiotic strains

Figure 1 illustrates the 16s ribosomal banding pattern for each of the six selected strains. 246 Sequencing of these bands and comparison with available sequences in the NCBI database 247 revealed that each of these strains were novel isolates and had not been previously described 248 (i.e. no 100% match was found). The closest available sequences identified these strains as 249 Lactobacillus murinus/ruminus (AHC1222, AHC3133, AHC5323 and AHC6331), 250 Bifidobacterium globosum/pseudolongum (AHCF) and Bifidobacterium animalis (AHC7). 251 The six bacterial strains were deposited with the National Collections of Industrial Food 252 and Marine Bacteria (NCIMB), Aberdeen, UK and were assigned the following 253 254 accession numbers - AHC1222 (NCIMB 41194); AHC3133 (NCIMB 41195); AHC5323 (NCIMB 41196); AHC6331 (NCIMB 41197); AHCF (NCIMB 41198); AHC7 (NCIMB 255 41199). 256

257

258 *3.4 Adherence to intestinal epithelial cells*

The six strains adhered to some degree to HT-29 cells but none of the lactobacillus strains adhered as well as the positive control organism UCC118 (Figure 2). Both bifidobacterial strains (AHCF and AHC7) adhered to intestinal epithelial cells to a significantly greater extent than all other strains tested.

263

264 *3.5 Gastrointestinal transit in mice*

All strains transited the murine gastrointestinal tract validating the *in vitro* selection criteria which suggested that these strains could survive physiologically relevant pH conditions and bile concentrations (Figure 3). The highest transit levels were observed for the two Bifidobacteria isolates AHCF and AHC7. None of the strains colonised the murine gut as following cessation of feeding no rifampicin resistant colonies were observed.

270

271 3.6 Murine Salmonella typhimurium challenge

272 Following challenge with *Salmonella typhimurium*, liver and spleen recovery of the pathogen

273 was assessed in *Lactobacilli*, *Bifidobacteria* and placebo-fed animals. In placebo-fed

animals, the mean recovery of *Salmonella typhimurium* was 1×10^9 CFU/g and 2×10^8 CFU/g

- of liver and spleen respectively. Two of the six tested probiotic organisms significantly
- reduced translocation of *S. typhimurium* to both liver and spleen 7 days following the initial
- infection (Figure 4). These strains were AHC7 and AHC3133.

279 *3.7 Influence of probiotic consumption on the canine microbiota*

One of the canine isolates, Bifidobacterium animalis AHC7, was selected on the basis of its 280 in vitro and in vivo properties for assessment in a canine study. Bifidobacterium animalis 281 AHC7 was consumed daily for 6 weeks and a comprehensive assessment of the canine fecal 282 microbiota was performed prior to and after probiotic consumption. As there was no 283 significant difference in bacterial counts between the two baseline determinations (days -10 284 and -1), we averaged the two baseline counts for each micro-organism in order to 285 generate one baseline value for comparison to later time-points during the study period. 286 Total fecal Clostridia counts were significantly reduced at weeks 5 and 6 in the 287 Bifidobacterium animalis AHC7-fed animals while assessment of individual Clostridia 288 species revealed that C. difficile numbers, but not C. perfringens, was significantly reduced 289 by week 6 (Table 1). C. difficile numbers were significantly reduced at week 6 when 290 291 compared to each baseline value individually (day -10 or day -1) or the mean baseline count. The number of total aerobes, Bacteroides, E. coli, Lactobacilli or Bifidobacteria were 292 293 not affected by probiotic feeding. Daily food intake and weekly body weights were not 294 significantly influenced by probiotic administration (data not shown).

296 4. Discussion

This report describes the successful isolation and characterisation of a novel bank of strains 297 from the canine gastrointestinal tract. Using a battery of in vitro and in vivo screening 298 methods, the commensal Bifidobacterium animalis AHC7 was selected as the most suitable 299 probiotic candidate from this strain bank. The basis for the selection of this microbe was not 300 due to any single characteristic in particular. Indeed, Bifidobacterium animalis AHC7 did not 301 rank as the most suitable strain in every assay system, however, Bifidobacterium animalis 302 AHC7 was the most consistent strain in receiving a high ranking and displayed the best 303 combination of all the putative probiotic features tested such as gastrointestinal transit, 304 stability, epithelial adherence, in vitro and in vivo anti-microbial activity. Upon further 305 examination in a canine feeding study, the commensal organism had a significant beneficial 306 effect on the canine microbiota as evidenced by the reduction in total Clostridia levels and 307 308 Clostridium difficile numbers.

Previous attempts at the isolation of commensal organisms from dogs have largely used 309 canine feces while few attempts had been made to isolate adherent commensal bacteria 310 311 directly from the canine intestinal mucosa. The fecal bacterial community is representative of the luminal contents of the large bowel but the adherent population is likely to be better 312 adapted to the host and may provide a more efficient barrier to infection. In addition, certain 313 commensal organisms may lose viability rapidly once shed in feces. This is supported by a 314 previous study which was unable to isolate Bifidobacteria from canine feces (Greetham et al., 315 2002). However, multiple Bifidobacteria species were isolated in our study and also in 316 another study which used intestinal samples (Kim and Adachi, 2007). 317

One of the parameters that was used in the selection of a probiotic strain for use in companion animals was the ability of a strain to survive technological processes, such as freeze-drying, and to survive storage at room temperature. This is an essential characteristic

for the future development of a companion animal product containing a probiotic. The poor quality control of existing pet food products which are labelled as containing probiotics was highlighted by Weese **and** Arroyo (2003). Out of the 19 commercial diets that were examined, none contained all the organisms listed and 5 contained no detectable viable bacteria. In order for a probiotic to exert a health benefit it should be delivered as a live micro-organism at a high enough dose to impact the host enteric community.

Consumption of *Bifidobacterium animalis* AHC7 by dogs resulted in **decreased** fecal levels 327 of *Clostridia* and *Clostridium difficile*. The *Clostridia* species are generally regarded as 328 opportunistic pathogens and *Clostridium difficile* is well described as the causative agent of 329 antibiotic associated diarrhoea and pseudomembraneous colitis in susceptible humans (Pepin 330 et al., 2004; Brazier 2008). The acquisition of C. difficile during hospitalization of dogs is 331 also associated with the development of diarrhea (Clooten et al., 2008). The elimination of C. 332 difficile from the canine gut may not only improve canine gastrointestinal health but may also 333 help reduce the risk of human infection due to owner-pet interactions. The risk for human 334 contamination is highly significant as highlighted by one study that detected shedding of 335 Clostridium difficile in 58% of visitation dogs in a healthcare setting (Lefebvre et al., 2006). 336 Bifidobacterium animalis AHC7 consumption did not increase the total level of 337 Bifidobacteria detected in canine feces. However, we have described unusually high 338 Bifidobacterium fecal counts in this canine cohort suggesting that the selective media 339 340 used may allow for the growth of other, non-Bifidobacterium, species and therefore the bifidobacterial count data should be treated with caution. Indeed, previous studies have 341 highlighted the non-selective nature of media for enumeration of Bifidobacteria in non-342 343 human fecal samples (Hartemink and Rombouts, 1999).

The bacterial population within the GI tract of mammals constitutes a metabolically active organ that detoxifies potentially harmful substances in the diet (Murphy et al., 2009) and acts

as a significant barrier to infection by exogenous pathogenic microorganisms. At present, our 346 picture of human GI-tract ecology is far from complete, even less so for companion animals 347 such as cats and dogs. This study adds to a growing literature on the canine microbiota by 348 describing the isolation and screening of canine-derived bacterial strains with commensal 349 traits. The results demonstrate that Bifidobacterium animalis AHC7 has significant potential 350 for improving canine gastrointestinal health. However, the mechanism of action is uncertain 351 and is likely to depend on individual characteristics of the strain itself and the clinical 352 condition for which it is used. 353

Cool

355 **References**

356	Baillon, M.L., Marshall-Jones, Z.V., Butterwick, R.F., 2004. Effects of probiotic
357	Lactobacillus acidophilus strain DSM13241 in healthy adult dogs. Am. J. Vet. Res. 65, 338-
358	43.

Brazier, J.S., 2008. *Clostridium difficile*: from obscurity to superbug. Br. J. Biomed.
Sci. 65, 39-44.

Clooten, J., Kruth, S., Arroyo, L., Weese, J.S., 2008. Prevalence and risk factors for
 Clostridium difficile colonization in dogs and cats hospitalized in an intensive care unit. Vet.
 Microbiol. 129, 209-14.

Dunne, C., O'Mahony, L., Murphy, L., Thornton, G., Morrissey, D., O'Halloran, S.,
Feeney, M., Flynn, S., Fitzgerald, G., Daly, C., Kiely, B., O'Sullivan, G.C., Shanahan, F.,

366 Collins, J. K., 2001. In vitro selection criteria for probiotic bacteria of human origin:

367 correlation with in vivo findings. Am. J. Clin. Nutr. 73, 386S–392S.

Hartemink, R., Rombouts, F.M., 1999. Comparison of media for the detection of
bifidobacteria, lactobacilli and total anaerobes from faecal samples. J. Microbiol. Methods
36, 181-192.

371 Greetham, H.L., Giffard, C., Hutson, R.A., Collins, M.D., Gibson, G.R., 2002.
372 Bacteriology of the Labrador dog gut: a cultural and genotypic approach. J. Appl. Microbiol.

373 93, 640-646.

Kim, S.Y., Adachi, Y., 2007. Biological and genetic classification of canine intestinal
lactic acid bacteria and *bifidobacteria*. Microbiol. Immunol. 51, 919-928.

 people in Ontario: implications for infection control. J. Hosp. Infect. 62, 458-466. McCoy, S., Gilliland, S.E., 2007. Isolation and characterization of <i>Lactobacillus</i> species having potential for use as probiotic cultures for dogs. J. Food Sci. 72, M94-97. Metchnikoff, E., 1907. The Prolongation of Life: Optimistic Studies. Mitchell, C., Ed William Heinemann, London. pp. 161–183. Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kicly, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and 	376	Lefebvre, S.L., Waltner-Toews, D., Peregrine, A.S., Reid-Smith, R., Hodge, L.,
 McCoy, S., Gilliland, S.E., 2007. Isolation and characterization of <i>Lactobacillus</i> species having potential for use as probiotic cultures for dogs. J. Food Sci. 72, M94-97. Metchnikoff, E., 1907. The Prolongation of Life: Optimistic Studies. Mitchell, C., Ed William Heinemann, London. pp. 161–183. Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokin 	377	Arroyo, L.G., Weese, J.S., 2006. Prevalence of zoonotic agents in dogs visiting hospitalized
 species having potential for use as probiotic cultures for dogs. J. Food Sci. 72, M94-97. Metchnikoff, E., 1907. The Prolongation of Life: Optimistic Studies, Mitchell, C., Ed William Heinemann, London. pp. 161–183. Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. Lactobacillus and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	378	people in Ontario: implications for infection control. J. Hosp. Infect. 62, 458-466.
 Metchnikoff, E., 1907. The Prolongation of Life: Optimistic Studies, Mitchell, C., Ed William Heinemann, London. pp. 161–183. Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	379	McCoy, S., Gilliland, S.E., 2007. Isolation and characterization of Lactobacillus
 William Heinemann, London. pp. 161–183. Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	380	species having potential for use as probiotic cultures for dogs. J. Food Sci. 72, M94-97.
 Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G., Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	381	Metchnikoff, E., 1907. The Prolongation of Life: Optimistic Studies. Mitchell, C., Ed.
 Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics- Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokin 	382	William Heinemann, London. pp. 161–183.
 Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107. O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	383	Murphy, C., Murphy, S., O'Brien, F., O'Donoghue, M., Boileau, T., Sunvold, G.,
 O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	384	Reinhart, G., Kiely, B., Shanahan, F., O'Mahony, L., 2009. Metabolic activity of probiotics-
 688–693. O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	385	Oxalate degradation. Vet. Microbiol. 136(1-2), 100-107.
 O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	386	O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7,
 diseases. Scientific World Journal. 7, 31-46. O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	387	688–693.
 O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A., Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	388	O'Hara AM, Shanahan F, 2007. Mechanisms of action of probiotics in intestinal
 Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal- induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	389	diseases. Scientific World Journal. 7, 31-46.
 induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	390	O'Mahony, C., Scully, P., O'Mahony, D., Murphy, S., O'Brien, F., Lyons, A.,
 activation. PLoS Pathog. 4, e1000112. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	391	Sherlock, G., MacSharry, J., Kiely, B., Shanahan, F., O'Mahony, L., 2008. Commensal-
 O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	392	induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB
 G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. <i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir 	393	activation. PLoS Pathog. 4, e1000112.
396 <i>bifidobacterium</i> in irritable bowel syndrome: symptom responses and relationship to cytokir	394	O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan,
	395	G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. Lactobacillus and
397 profiles. Gastroenterology 128, 541-551.	396	bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine
	397	profiles. Gastroenterology 128, 541-551.

398	Pascher, M., Hellweg, P., Khol-Parisini, A., Zentek, J., 2008. Effects of a probiotic
399	Lactobacillus acidophilus strain on feed tolerance in dogs with non-specific dietary
400	sensitivity. Arch Anim Nutr. 62, 107-116.
401	Pepin, J., Valiquette, L., Alary, M. E., Villemure, P., Pelletier, A., Forget, K., Pepin,
402	K. & Chouinard, D., 2004. Clostridium difficile associated diarrhea in a region of Quebec
403	from 1991 to 2003: a changing pattern of disease severity. CMAJ 171, 466–472.
404	Ley, R.E., Lozupone, C.A., Hamady, M., Knight, R., Gordon, J.I., 2008. Worlds
405	within worlds: evolution of the vertebrate gut microbiota. Nat. Rev. Microbiol. 6, 776-788.
406	Swanson, K.S., Grieshop, C.M., Flickinger, E.A., Bauer, L.L., Chow, J., Wolf, B.W.,
407	Garleb, K.A., Fahey, G.C. Jr, 2002. Fructooligosaccharides and Lactobacillus acidophilus
408	modify gut microbial populations, total tract nutrient digestibilities and fecal protein
409	catabolite concentrations in healthy adult dogs. J. Nutr. 132, 3721-3731.
410	Vahjen, W., Männer, K., 2003. The effect of a probiotic Enterococcus faecium
411	product in diets of healthy dogs on bacteriological counts of Salmonella spp., Campylobacter
412	spp. and <i>Clostridium</i> spp. in faeces. Arch Tierernahr. 57, 229-233.
413	Van Pijkeren, J.P., Canchaya, C., Ryan, K.A., Li, Y., Claesson, M.J., Sheil, B.,
414	Steidler, L., O'Mahony, L., Fitzgerald, G.F., van Sinderen, D., O'Toole, P.W., 2006.
415	Comparative and functional analysis of sortase-dependent proteins in the predicted secretome
416	of Lactobacillus salivarius UCC118. Appl. Environ. Microbiol. 72, 4143-4153.
417	Weese, J.S., Arroyo, L., 2003. Bacteriological evaluation of dog and cat diets that
418	claim to contain probiotics. Can. Vet. J. 44, 212-216.
419	Whorwell, P.J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L.,
420	Kiely, B., Shanahan, F., Quigley, E.M., 2006. Efficacy of an encapsulated probiotic

- 421 *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. Am. J.
- 422 Gastroenterol. 101,1581-1590.

424 Legends

425 Table 1. Canine microbiota following *Bifidobacterium animalis* AHC7 consumption

- 426 Eleven animals consumed the putative probiotic *Bifidobacterium animalis* AHC7 for 6 weeks
- 427 and the fecal bacterial communities were assessed prior to and following feeding at weeks 4,
- 428 5 and 6. Total *Clostridia* and *Clostridium difficile* numbers were significantly reduced by
- 429 *Bifidobacterium animalis* AHC7 consumption. Results are expressed as the mean log CFU/g
- 430 for each time-point.

431 Figure 1. Intergenic spacer PCR products

432 The banding patterns for the PCR products of each strain on agarose gels stained with EtBr is

illustrated. Multiple products are observed for the *Lactobacillus* strains while single bands are
evident for the *Bifidobacterium* strains.

435 Figure 2. Adhesion to epithelial cells

Each bacterial strain adheres to HT-29 intestinal epithelial cells while the *Bifidobacterium*

437 strains adhere at a significantly higher level compared to the *Lactobacillus* strains (indicated

438 by the asterix "*"). Results are expressed as the mean % of incubated bacterial cells that

adhere to the epithelial cells (n=6 different wells/strain) +/- SD.

440 Figure 3. Murine gastrointestinal transit

441 Rifampicin-resistant strains were consumed by mice for 7 days and fecal recovery of

rifampicin-resistant colonies was performed on days 0, 1, 4, 7 and 5 days following cessation


- 443 of feeding. All strains transited the murine gastrointestinal tract at a significant level during
- 444 feeding but were not recovered in feces following cessation of consumption. Results are
- expressed as the mean CFU/gram of feces for each group of animals (n=8 animals per group).


446 Figure 4. Inhibition of *Salmonella typhimurium* translocation in a murine model


- 447 Translocation and survival of *Salmonella typhimurium* at systemic sites (liver and spleen)
- 448 was assessed in animals that had previously consumed a *Lactobacillus* or *Bifidobacterium*
- 449 strain for 3 weeks. AHC7 and AHC3133 significantly reduced Salmonella typhimurium
- 450 translocation with a p-value <0.05 compared to the placebo group (*). Results are


ي مي ال

- 451 expressed as the mean colony forming units (cfu) recovery of *Salmonella typhimurium* from
- 452 liver and spleen (n=12 animals per group).









Bacterial Strain	Baseline	Week 4	Week 5	Week 6	Pooled	P-value
					SEM	
Total Anaerobes	10.44	10.36	10.11	10.21	9.64	0.23
Total Aerobes	9.17	8.73	8.74	8.99	8.73	0.72
Bacteroides	6.26	5.65	6.02	6.26	5.71	0.22
Total Clostridia	9.58	9.41	8.95	9.12	8.93	0.04
C. perfringens	7.16	7.54	7.14	7.37	6.93	0.40
C. difficile	7.44	6.80	7.07	5.81	6.76	0.05
E. coli	6.43	6.41	6.94	7.20	6.76	0.62
Lactobacilli	9.79	9.71	9.30	9.44	9.23	0.62
Bifidobacteria	10.09	10.16	9.81	10.04	9.43	0.48

Table 4. Canine microbiota following Bifidobacterium animalis AHC7 consumption

م م